Compare Amylx Pharmaceuticals Inc (AMLX) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.58 (market cap $2.64B), while State Street SPDR S&P Homebuilders ETF trades at $108.69. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | XHB | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $24.19 | $121.36 |
52-Week Low | $7.82 | $94.86 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
XHB trades at $108.22, down slightly by 0.02% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights mixed housing data, including a 1.6% rise in new home sales in June 2026 (Census Bureau, 2026-07-24) but a 2.4% drop in existing home sales (CNBC, 2026-07-09). The ETF benefits from a new housing affordability law (Zacks Investment Research, 2026-07-13), though financial ratios are unavailable.
Outlook is cautiously optimistic due to policy support and technical strength, but risks include high mortgage rates and volatile home sales. Investors should weigh bullish momentum against macroeconomic headwinds in the housing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
